Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tecotabart, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omoprubart, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rezorstobart, an antibody targeting KLRB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nelmastobart, an antibody targeting BTN1A1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mozistobart, an antibody targeting CD22.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nezastomig, an antibody targeting PSMA × CD28.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fanastomig, an antibody targeting LAG3 × PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ibentatug, an antibody targeting CSP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Micvotabart, an antibody targeting FN extracellular domain B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Evalstotug, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cugrastomig, an antibody targeting LAG3 × PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dibotatug, an antibody targeting KLRD1.